Tadalafil and Acetazolamide Versus Acetazolamide for the Prevention of Severe High-Altitude Illness

Authors


  • The study was presented at the 12th Conference of the International Society of Travel Medicine, Boston, USA, 8–12 May, 2011 (FC4).

Corresponding Author: Professor Eli Schwartz, MD, Center of Geographic Medicine, Sheba Medical Center, 52621 Tel Hashomer, Israel. E-mail: elischwa@post.tau.ac.il

Abstract

We report an open-label study comparing tadalafil and acetazolamide (n = 24) versus acetazolamide (n = 27) for prevention of high-altitude illness (HAI) at Mt. Kilimanjaro. Tadalafil group had lower rates of severe HAI compared with controls (4% vs 26%, p = 0.03), mostly because of decreased high-altitude pulmonary edema rates (4% vs 22%, p = 0.06).

Ancillary